Three Seasons Wealth LLC Has $991,000 Stock Holdings in Pacira BioSciences, Inc. $PCRX

Three Seasons Wealth LLC increased its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 87.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 43,835 shares of the company’s stock after acquiring an additional 20,504 shares during the quarter. Three Seasons Wealth LLC’s holdings in Pacira BioSciences were worth $991,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Northwestern Mutual Wealth Management Co. raised its holdings in Pacira BioSciences by 5,900.0% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 1,500 shares of the company’s stock worth $39,000 after purchasing an additional 1,475 shares during the period. Kestra Advisory Services LLC acquired a new position in shares of Pacira BioSciences in the 4th quarter valued at $48,000. Eurizon Capital SGR S.p.A. bought a new stake in shares of Pacira BioSciences in the 4th quarter valued at $51,000. Global Retirement Partners LLC increased its position in shares of Pacira BioSciences by 479.4% in the 4th quarter. Global Retirement Partners LLC now owns 2,028 shares of the company’s stock valued at $52,000 after buying an additional 1,678 shares in the last quarter. Finally, Hantz Financial Services Inc. raised its stake in Pacira BioSciences by 127.3% during the 4th quarter. Hantz Financial Services Inc. now owns 2,573 shares of the company’s stock worth $67,000 after buying an additional 1,441 shares during the period. Institutional investors and hedge funds own 99.73% of the company’s stock.

Pacira BioSciences Trading Up 1.3%

Shares of NASDAQ:PCRX opened at $25.33 on Thursday. Pacira BioSciences, Inc. has a 12 month low of $18.80 and a 12 month high of $27.64. The company has a quick ratio of 3.35, a current ratio of 4.73 and a debt-to-equity ratio of 0.56. The company’s fifty day simple moving average is $23.73 and its 200 day simple moving average is $23.18. The firm has a market cap of $996.74 million, a price-to-earnings ratio of 211.10 and a beta of 0.27.

Pacira BioSciences (NASDAQ:PCRX) last announced its earnings results on Thursday, April 30th. The company reported $0.60 earnings per share for the quarter, missing analysts’ consensus estimates of $0.61 by ($0.01). The company had revenue of $177.38 million during the quarter, compared to analyst estimates of $171.80 million. Pacira BioSciences had a return on equity of 10.24% and a net margin of 0.70%.Pacira BioSciences’s revenue for the quarter was up 5.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.65 earnings per share. As a group, research analysts forecast that Pacira BioSciences, Inc. will post 1.94 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on PCRX shares. Zacks Research upgraded Pacira BioSciences from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 7th. Weiss Ratings upgraded Pacira BioSciences from a “sell (d)” rating to a “sell (d+)” rating in a report on Wednesday, May 20th. Needham & Company LLC raised their price target on Pacira BioSciences from $30.00 to $32.00 and gave the stock a “buy” rating in a research report on Friday, May 1st. HC Wainwright reiterated a “buy” rating and set a $38.00 price objective on shares of Pacira BioSciences in a report on Wednesday, July 1st. Finally, Royal Bank Of Canada boosted their price objective on Pacira BioSciences from $22.00 to $24.00 and gave the company a “sector perform” rating in a research report on Friday, May 1st. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $29.40.

Insider Transactions at Pacira BioSciences

In other news, SVP Lauren Riker sold 6,115 shares of the company’s stock in a transaction dated Thursday, June 11th. The stock was sold at an average price of $23.50, for a total transaction of $143,702.50. Following the completion of the transaction, the senior vice president directly owned 62,284 shares of the company’s stock, valued at $1,463,674. This represents a 8.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Shawn Cross sold 12,941 shares of Pacira BioSciences stock in a transaction that occurred on Thursday, April 23rd. The shares were sold at an average price of $25.16, for a total value of $325,595.56. Following the completion of the sale, the chief financial officer directly owned 105,341 shares in the company, valued at approximately $2,650,379.56. This represents a 10.94% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 31,115 shares of company stock worth $771,896. Corporate insiders own 6.40% of the company’s stock.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc is a specialty pharmaceutical company focused on developing and commercializing non-opioid, non-addictive pain management and regenerative health solutions. The company’s flagship product, EXPAREL, is a bupivacaine liposome injectable suspension designed to provide long-lasting postsurgical analgesia. EXPAREL is used by clinicians across a broad range of surgical procedures to reduce reliance on opioid medications and to help manage acute postoperative pain.

In addition to its marketed offering, Pacira maintains an active pipeline of investigational products aimed at addressing unmet needs in pain management and inflammation control.